Pcaf Modulates Polyglutamine Pathology in a *Drosophila* Model of Huntington's Disease

Laszlo Bodai^{a, e} Judit Pallos^a Leslie Michels Thompson^{b, c} J. Lawrence Marsh^{a, d}

Departments of ^aDevelopmental and Cell Biology, ^bPsychiatry and Human Behavior, ^cNeurobiology and Behavior, and ^dPathology, University of California Irvine, Irvine, Calif., USA; ^eDepartment of Biochemistry and Molecular Biology, University of Szeged, Szeged, Hungary

Key Words

Polyglutamine · Huntington's disease · Histone acetyltransferase · Pcaf · Nejire · *Drosophila*

Abstract

Huntingtin peptides with elongated polyglutamine domains, the root causes of Huntington's disease, hinder histone acetylation, which leads to transcriptional dysregulation. However, the range of acetyltransferases interacting with mutant Huntingtin has not been systematically evaluated. We used genetic interaction tests in *Drosophila* to determine whether specific acetyltransferases belonging to distinct protein families influence polyglutamine pathology. We found that flies expressing a mutant form of the Huntingtin protein (Httex1pQ93) exhibit reduced viability, which is further decreased by partial loss of *Pcaf* or *nejire*, while the tested MYST family acetyltransferases did not affect pathology. Reduced levels of *Pcaf* also led to the increased degeneration of photoreceptor neurons in the retina. Overexpression of *Pcaf*, however, was not sufficient to ameliorate these phenotypes, and the level of soluble *Pcaf* is unchanged in Httex1pQ93-expressing flies. Thus, our results indicate that while *Pcaf* has a significant impact on Huntington's disease pathology, therapeutic strategies aimed at elevating its levels are likely to be ineffective in ameliorating Huntington's disease pathology; however, strategies that aim to increase the specific activity of *Pcaf* remain to be tested.

Copyright © 2011 S. Karger AG, Basel

Huntington's disease (HD) belongs to a group of neurodegenerative diseases caused by the expansion of a polyglutamine (polyQ) domain in the affected protein. Transcriptional dysregulation is one of the molecular mechanisms underlying polyQ pathology [1]. The effect on transcription can be partially explained by the fact that mutant Huntingtin (Htt) binds to several transcription factors [1]. One group of affected factors is the histone acetyltransferases (HATs) [2]. Mutant Htt binds to CBP, p300 and Pcaf and inhibits their activities leading to a decreased level of histone acetylation [3]. Furthermore, mutant Htt depletes CBP by targeting it for degradation [4], and depletion of CBP is associated with cell death in HD models [5]. The importance of altered protein acetylation in HD is underscored by experiments showing that inhibition of histone deacetylase enzymes ameliorates HD phenotypes in several animal models [3, 6, 7]. Although the HATs belong to different protein families, for example the GNAT (e.g. Pcaf), the MYST and the CBP/p300 families [8], most studies to date have focused only on the role of CBP in disease pathogenesis leaving the role of other HATs unknown. Here we describe a genetic interaction study designed to determine whether HATs other than CBP are involved in polyQ pathogenesis.

To investigate the consequences of reduced HAT activity on polyQ pathology, we used a *Drosophila* model of HD, which was previously shown to be sensitive to acetylation levels [3, 6]. We compared the phenotypes of flies that express Httex1pQ93 in the nervous system with their

Table 1. Results of genetic interaction crosses involving HAT mutants and Htt

HAT family	Affected gene	Mutation	Relative eclosion, %	p value	n	HAT mutation; Htt exp.	Htt exp.	HAT mutation; no Htt	No Htt
CBP/p300	<i>nej</i>	<i>nej</i> ³	67.3	<0.01	1,268	150	209	469	440
MYST	<i>enok</i>	<i>enok</i> ²	92.5	0.47	2,341	202	208	989	942
	<i>mof</i>	<i>mof</i> ²	100.5	0.96	1,437	232	206	528	471
	<i>CG1894</i>	<i>Df(3R)Ex6259</i>	83.7	0.12	1,432	197	215	533	487
GNAT	<i>Pcaf</i>	<i>Pcaf</i> ^{E333St}	49.4	<0.001	3,419	114	215	1,600	1,490
		<i>Df(3L)iro-2</i>	54	<0.001	4,163	340	612	1,629	1,582
		<i>UAS-Pcaf</i> ¹	102.2	0.89	1,002	99	88	427	388
		<i>UAS-Pcaf</i> ^{3B}	118.4	0.3	785	109	93	290	293
		<i>UAS-Pcaf</i> ^{5L}	135.5	0.08	867	89	74	331	373
		<i>UAS-Pcaf</i> ⁷	126.2	0.32	390	51	46	137	156

The relative eclosion rates, statistical significance, number of all scored progenies (n) and the number of offspring in the four genotype categories are shown for loss of function HAT mutants, HAT deletions and UAS-Pcaf overexpressor lines.

siblings that, in addition, carry a HAT mutation as well. We found that partial loss of *Pcaf* (the single fly homolog of human Pcaf and Gcn5) or *nejire/dCBP* (*nej*, homolog of human CBP) by the *Pcaf*^{E333St} or *nej*³ mutations, respectively, significantly reduced the viability of *Htt*-expressing flies, while reducing the MYST family acetyltransferases *enok*, *mof* or *CG1894* did not have a significant effect on pathology (table 1).

Since the role of CBP is well established in HD pathogenesis, we sought to investigate in detail the effect of *Pcaf*, which was not previously characterized. First, we tested whether *Df(3L)iro-2*, an independent deletion that removes the *Pcaf* gene but does not share the same genetic background as the *Pcaf*^{E333St} null allele, has the same effect. We found that *Htt*-expressing flies heterozygous for *Df(3L)iro-2* also exhibited significantly reduced viability by 46% (table 1). Next we asked whether reduced Pcaf levels lead to neuronal toxicity. We compared *Htt*-expressing control flies with siblings expressing *Htt* and also carrying the *Pcaf*^{E333St} allele, and found that the average number of rhabdomeres (light gathering structures of photoreceptor neurons) per ommatidium decreased from 4.66 ± 0.08 to 4.32 ± 0.11 ($n = 10$, $p = 0.021$), as measured by the pseudopupil assay. We obtained a similar result with the *Df(3L)iro-2* deletion, where the average number of rhabdomeres decreased from 4.78 ± 0.11 to 4.42 ± 0.03 ($n = 7$, $p = 0.028$), indicating that reduced Pcaf levels enhance neurodegeneration.

Since reducing *Pcaf* is deleterious, we next asked whether *Htt* pathology could be ameliorated by overexpressing *Pcaf*. We generated transgenic flies expressing a full-length

Pcaf cDNA under UAS control and tested four independent *UAS-Pcaf* transgenic strains. We found that the eclosion rates of flies expressing both *Pcaf* and *Htt* simultaneously in the nervous system were slightly, albeit not significantly, higher than those of mutant *Htt*-expressing control siblings (table 1). Similarly, we found no significant difference in neurodegeneration between flies coexpressing *Htt* and *Pcaf*, compared to siblings expressing only *Htt*, as measured by the pseudopupil assay (data not shown).

In addition, we sought to determine whether the quantity of soluble Pcaf protein is altered in *Httex1pQ93*-expressing flies and found that mutant *Htt* expression does not result in the reduction of the level of Pcaf (fig. 1).

Taken together, we found that partial loss of *Pcaf* significantly enhanced polyglutamine pathology, but the level of Pcaf was not reduced by mutant *Htt*, and we could not rescue HD phenotypes by the overexpression of *Pcaf*, indicating that the interaction of mutant *Htt* and Pcaf does not involve the depletion of soluble Pcaf by either degradation or sequestration to insoluble aggregates. This result, however, does not exclude the possibility that a soluble toxic form of *Htt* might inhibit the function of either Pcaf itself or of Pcaf-containing complexes. Since Pcaf acts as a catalytic subunit in large multiprotein complexes in metazoans [9], we speculate that its interaction with a polyQ peptide might cripple entire complexes, which cannot be rescued by overexpression of *Pcaf* alone. We conclude that although *Pcaf* has a significant impact on HD pathology, therapeutic strategies aimed at elevating the levels of Pcaf protein are unlikely to be effective in ameliorating HD pathology. The question, however,

Fig. 1. Mutant Huntingtin does not reduce the level of soluble Pcaf. Immunoblots of head extracts of Httex1pQ93-expressing flies (Htt) are shown next to wild-type control (no Htt), as well as larval extracts of homozygous *Pcaf*^{E333St} (Pcaf null).

remains open whether strategies that aim to increase the specific activity of Pcaf might be useful. Interestingly, of the three HAT families of proteins tested, only the GNAT and the CBP/p300 families exhibit a strong influence over HD pathology, while the MYST family members have decidedly less impact.

Materials and Methods

Stocks carrying the mutations *Pcaf*^{E333St}, *Df(3L)iro-2*, *Df(3R)Exel6259*, *enok*², *nej*³, and the pan-neuronal *elav-GAL4* driver *w^PUAS-GawB¹elav^{C155}* were from the Bloomington Drosophila Stock Center. The *moj*² allele was kindly provided by John C. Lucchesi (Emory University, Atlanta, Ga., USA). The *w^PUAS-Httex1p-Q93* transgenic line expressing the first exon of hu-

man Htt with a 93-residue-long polyQ repeat under UAS control was generated in our laboratory previously [3].

UAS-Pcaf transgenic lines were produced by cloning the full-length *Pcaf* cDNA from the GH11602 clone (from the Drosophila Genomics Resource Center, Bloomington, Indiana University) to the EcoRI site of pUAST, and generating transgenics by standard P element-mediated transformation.

Viability tests were done by crossing *elav>Gal4/Y HAT mutant/Marker* males to *Httex1pQ93/Httex1pQ93* females and scoring the number of offspring in the four genotype categories. Relative eclosion rates were calculated as the ratio of HAT mutant to HAT wild-type *Htt*-expressing siblings normalized by the ratio of HAT mutant to HAT wild-type siblings not expressing *Htt*. The statistical significance of differences in eclosion was determined by a χ^2 probe. Pseudopupul analysis was performed on 6-day-old females as described previously [3]; statistical significance was evaluated by unpaired t test.

Immunoblotting was performed on head extracts from 1-day-old flies using polyclonal antibodies against Pcaf/dGcn5 [10] and actin (Sigma A5060) with goat-anti-rabbit-HRP secondary antibody (Dako P0448); detection was done using Immobilon Western Chemiluminescent HRP substrate (Millipore).

Acknowledgements

The authors wish to thank John C. Lucchesi (Emory University, Atlanta, Ga., USA) and the Bloomington Drosophila Stock Center for providing fly stocks, the Drosophila Genomics Resource Center for cDNA clones and Sofia G. Georgieva (Institute of Gene Biology, Moscow, Russia) for the dGcn5 antibody. This work was supported by the National Institutes of Health (NS045283 to J.L.M., NS52789 to L.M.T.), the Hereditary Disease Foundation (HDF-24085), and the Huntington's Disease Society of America (35326).

References

- Riley BE, Orr HT: Polyglutamine neurodegenerative diseases and regulation of transcription: assembling the puzzle. *Genes Dev* 2006;20:2183–2192.
- Bodai L, Pallos J, Thompson LM, Marsh JL: Altered protein acetylation in polyglutamine diseases. *Curr Med Chem* 2003;10:2577–2587.
- Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, Kazantsev A, Schmidt E, Zhu YZ, Greenwald M, Kurokawa R, Housman DE, Jackson GR, Marsh JL, Thompson LM: Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. *Nature* 2001;413:739–743.
- Cong S, Peppers BA, Evert BO, Rubinsztein DC, Roos RAC, van Ommen GB, Dorsman JC: Mutant huntingtin represses CBP, but not p300, by binding and protein degradation. *Mol Cell Neurosci* 2005;30:560–571.
- Jiang H, Poirier MA, Liang Y, Pei Z, Weiskittel CE, Smith WW, DeFranco DB, Ross CA: Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. *Neurobiol Dis* 2006;23:543–551.
- Pallos J, Bodai L, Lukacsovich T, Purcell JM, Steffan JS, Thompson LM, Marsh JL: Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. *Hum Mol Genet* 2008;17:3767–3775.
- Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PAS, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, Bates GP: Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. *Proc Natl Acad Sci USA* 2003;100:2041–2046.
- Sterner DE, Berger SL: Acetylation of histones and transcription-related factors. *Microbiol Mol Biol Rev* 2000;64:435–459.
- Nagy Z, Tora L: Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. *Oncogene* 2007;26:5341–5357.
- Lebedeva LA, Nabirochkina EN, Kurshakova MM, Robert F, Krasnov AN, Evgenyev MB, Kadonaga JT, Georgieva SG, Tora L: Occupancy of the Drosophila hsp70 promoter by a subset of basal transcription factors diminishes upon transcriptional activation. *Proc Natl Acad Sci USA* 2005;102:18087–18092.